BlackRock’s Petros Pharmaceuticals PTPI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-645
| Closed | -$1.11K | – | 5568 |
|
|
2025
Q1 | $1.11K | Hold |
645
| – | – | ﹤0.01% | 5332 |
|
|
2024
Q4 | $6.35K | Hold |
645
| – | – | ﹤0.01% | 5207 |
|
|
2024
Q3 | $5.76K | Sell |
645
-15
| -2% | -$141 | ﹤0.01% | 5034 |
|
|
2024
Q2 | $7.55K | Hold |
660
| – | – | ﹤0.01% | 5092 |
|
|
2024
Q1 | $24.4K | Sell |
660
-4
| -0.6% | -$141 | ﹤0.01% | 5000 |
|
|
2023
Q4 | $23.4K | Buy |
664
+4
| +0.6% | +$143 | ﹤0.01% | 5069 |
|
|
2023
Q3 | $28.6K | Hold |
660
| – | – | ﹤0.01% | 5092 |
|
|
2023
Q2 | $33.5K | Hold |
660
| – | – | ﹤0.01% | 5134 |
|
|
2023
Q1 | $23K | Hold |
660
| – | – | ﹤0.01% | 5236 |
|
|
2022
Q4 | $38.5K | Hold |
660
| – | – | ﹤0.01% | 5274 |
|
|
2022
Q3 | $84K | Hold |
660
| – | – | ﹤0.01% | 5224 |
|
|
2022
Q2 | $139K | Sell |
660
-107
| -14% | -$26.8K | ﹤0.01% | 5138 |
|
|
2022
Q1 | $300K | Buy |
767
+689
| +883% | +$290K | ﹤0.01% | 5016 |
|
|
2021
Q4 | $65K | Buy |
78
+4
| +5% | +$2.34K | ﹤0.01% | 5366 |
|
|
2021
Q3 | $38K | Sell |
74
-2
| -3% | -$1.3K | ﹤0.01% | 5315 |
|
|
2021
Q2 | $59K | Buy |
76
+3
| +4% | +$2.4K | ﹤0.01% | 5160 |
|
|
2021
Q1 | $68K | Buy |
73
+19
| +35% | +$17.9K | ﹤0.01% | 4884 |
|
|
2020
Q4 | $59K | Buy |
+54
| New | +$50.8K | ﹤0.01% | 4650 |
|
BlackRock's PTPI Position: Q2 2025 in Review
BlackRock sold out of Petros Pharmaceuticals (PTPI) in Q2 2025, closing a stake of 645 shares — an estimated $1.11K sold.
BlackRock first reported a position in PTPI in Q4 2020 and held it in 18 quarters. The position peaked at $300K in Q1 2022. 0 funds tracked by Wall St. Rank hold PTPI as of Q2 2025.
- BlackRock reported no remaining Petros Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- BlackRock sold 645 Petros Pharmaceuticals shares in Q2 2025, an estimated $1.11K.
- BlackRock first reported a position in Petros Pharmaceuticals in Q4 2020 and held it in 18 quarters.
- BlackRock's Petros Pharmaceuticals position peaked at $300K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q2 2025.
Based on BlackRock's 13F filing for Q2 2025, filed 12 Aug 2025.